SCIENCE
TSMT
T-sphaera Multivalency Therapy
T-sphaera’s 24-mer architecture enables multivalent binder display, driving enhanced avidity and receptor clustering for superior therapeutic activity.
The Challenge
Structural Limitations of
Conventional Antibodies
- Limited valency and avidity
- Limited control over target clustering
- Fixed target/binder ratio (typically 1:1)
Our Solution
T-sphaera Solutions
- Multivalent binder display enables enhanced avidity
- Multivalency enables enhanced target clustering
- Tunable binder composition enables flexible target engagement